Unichem Labs gets USFDA nod to market muscle spasm tablets

The company has received abbreviated new drug application (ANDA) approval to market its Cyclobenzaprine Hydrochloride tablets USP 5 mg, 7.5 mg and 10 mg from the United States Food and Drug Administration (USFDA), Unichem Labs said in a filing to the BSE.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news